A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors.
Benjamin GarmezyMitesh J BoradRastislav BahledaCesar A PerezLi-Tzong ChenShumei KatoDo Youn OhPaul SeversonBetty Y TamCheng S QuahJames J HardingPublished in: Cancer research communications (2024)
The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable PK parameters, though further dose escalation was required to nominate the MTD/RP2D.